RxDoctor Payments Data

Jennifer Hartley

Acute Care · Seattle, WANPI 1609126606

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $82,006 of the $121,328 with a category attached, or 67.6%. AbbVie accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $99,420, more than ten times the $1,007 reported in 2021. Among acute care clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$121,328in general payments, 2019–2025

Across 421 payments — averaging $288.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$121K
  • Galderma Laboratories, L.p.$205
  • Astellas Pharma US Inc$146

What the payments were for

  • Consulting fees$10,2238%
  • Speaking & faculty fees$82,00668%
  • Travel & lodging$17,74415%
  • Food & beverage$10,6619%
  • Education$6951%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)416$120,976
Galderma Laboratories, L.p.2$205
Astellas Pharma US Inc3$146

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,328 in reported general payments places this provider in the 95th percentile of 135 acute care providers in Washington.

See all acute care providers in Washington →

Other acute care in Seattle

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →